With regard to the phase I/II clinical trial named MRTX849‐001 currently ongoing (NCT 03785249), MRTX849 safety and antitumor activity has been reported in patients with NSCLC, colorectal cancer (CRC) and appendiceal cancers with KRAS G12C mutation. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.